We speculated that the stroke prevention effects of SGLT2 inhibitors may differ for different renal function levels in diabetic patients, being more pronounced in those with more advanced renal impairment, e.g., eGFR < 45 mL/min/1.73 m2, via their effects on renal protection. Here, SLC5A2 is linked to stroke disorder.